The litigation targets the period between November 25, 2025, and May 4, 2026, during which Embecta repeatedly reaffirmed its fiscal year 2026 revenue guidance of up to $1.093 billion. The suit contends that management maintained this outlook despite knowing that the company’s primary product segment—which accounts for 85% of its portfolio—was failing. When the truth emerged, the stock price fell from $9.25 to $3.90, wiping out $5.35 per share.

According to the complaint, the revenue miss was largely driven by a $53 million shortfall in the pen needle category, representing over 70% of the total guidance reduction. The lawsuit alleges that Embecta masked underlying weakness in the U.S. retail channel, where patients were shifting to lower-cost alternatives and new insulin pen prescriptions were declining. While management described the segment as resolute, the company was reportedly facing structural market shifts caused by the rise of GLP-1 therapies and pump adoption. Shareholders seeking to participate in the recovery effort must file by August 17, 2026.